These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15572713)

  • 21. Surveillance for hepatocellular carcinoma in patients with liver cirrhosis in India.
    Aggarwal R
    Trop Gastroenterol; 2008; 29(4):183-6. PubMed ID: 19323085
    [No Abstract]   [Full Text] [Related]  

  • 22. Using global burden of hepatocellular cancer and liver cirrhosis as a driver to tackle preventable mortality and morbidity nationally and regionally.
    Bhala N; Ferguson JW; Rajoriya N; Newsome PN
    Hepatology; 2023 Apr; 77(4):1078-1080. PubMed ID: 36626619
    [No Abstract]   [Full Text] [Related]  

  • 23. [Incidence of hepatocellular carcinomas in liver cirrhosis].
    Lehmann FG; Martini GA
    Verh Dtsch Ges Inn Med; 1975; 81():1384-7. PubMed ID: 179239
    [No Abstract]   [Full Text] [Related]  

  • 24. Hepatocellular carcinoma and cirrhosis in Thailand: etiologic considerations of underlying cirrhosis.
    Suwangool P
    J Med Assoc Thai; 1980 May; 63(5):245-9. PubMed ID: 6248611
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevention of the occurrence of hepatocellular carcinoma in patients with cirrhosis.
    Ganne-Carrie N; Beaugrand M
    Hepatogastroenterology; 1998 Aug; 45 Suppl 3():1291-5. PubMed ID: 9730391
    [No Abstract]   [Full Text] [Related]  

  • 26. Viral hepatitis and hepatocellular carcinoma.
    Marrero CR; Marrero JA
    Arch Med Res; 2007 Aug; 38(6):612-20. PubMed ID: 17613352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing.
    Fattovich G; Llovet JM
    J Hepatol; 2006 Jun; 44(6):1013-6. PubMed ID: 16678654
    [No Abstract]   [Full Text] [Related]  

  • 28. Measurement of immunoreactive prothrombin, des-gamma-carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma.
    Ono M; Ohta H; Ohhira M; Sekiya C; Namiki M
    Am J Gastroenterol; 1990 Sep; 85(9):1149-54. PubMed ID: 1697141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocellular carcinoma and vitamin K.
    Mizuta T; Ozaki I
    Vitam Horm; 2008; 78():435-42. PubMed ID: 18374204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Is follow up of hepatocellular carcinoma in patients with liver cirrhosis justified?].
    Prat F
    Gastroenterol Clin Biol; 1992; 16(11):910. PubMed ID: 1282892
    [No Abstract]   [Full Text] [Related]  

  • 31. [Liver and hereditary alpha 1-antitrypsin deficiency].
    Feldmann G
    Gastroenterol Clin Biol; 1993; 17(2):83-93. PubMed ID: 8388836
    [No Abstract]   [Full Text] [Related]  

  • 32. Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence.
    Siegel AB; El-Serag HB
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):493-5. PubMed ID: 23984995
    [No Abstract]   [Full Text] [Related]  

  • 33. Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma.
    Seren S; Mutchnick M; Hutchinson D; Harmanci O; Bayraktar Y; Mutchnick S; Sahin K; Kucuk O
    Nutr Cancer; 2008; 60(6):729-35. PubMed ID: 19005972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and risk factors of hepatocellular carcinoma in patients with primary biliary cirrhosis.
    Macaron C; Hanouneh IA; Zein NN
    Hepatology; 2010 Dec; 52(6):2239; author reply 2239-40. PubMed ID: 21105115
    [No Abstract]   [Full Text] [Related]  

  • 35. [Vitamin K function mediated by activation of steroid and xenobiotic receptor].
    Azuma K; Inoue S
    Clin Calcium; 2009 Dec; 19(12):1770-8. PubMed ID: 19949268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current perspectives on chronic hepatitis B.
    Locarnini S; Thompson A
    Semin Liver Dis; 2013 May; 33(2):95-6. PubMed ID: 23749664
    [No Abstract]   [Full Text] [Related]  

  • 37. Portal hypertension and development of hepatocellular carcinoma: factors influencing significance in prognostic models.
    Christensen E
    J Hepatol; 2009 May; 50(5):848-9. PubMed ID: 19299028
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatocyte AgNOR protein quantitative expression is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis.
    Trerè D; Borzio M; Roncalli M; Derenzini M
    Eur J Histochem; 1997; 41 Suppl 2():149-50. PubMed ID: 9859825
    [No Abstract]   [Full Text] [Related]  

  • 39. Screening for hepatocellular carcinoma.
    Collier J; Sherman M
    Hepatology; 1998 Jan; 27(1):273-8. PubMed ID: 9425947
    [No Abstract]   [Full Text] [Related]  

  • 40. The increasing incidence of hepatocellular carcinoma.
    Ince N; Wands JR
    N Engl J Med; 1999 Mar; 340(10):798-9. PubMed ID: 10072416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.